Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 2 Spondylitis, Ankylosing 1 Signs and Symptoms 1 Lymphoma 1 Leukemia, Myeloid, Acute 1 Glioma 1 Epilepsy 1 Diarrhea 1 Colorectal Neoplasms 1 Breast Neoplasms 1 Brain Neoplasms 1 Arthritis, Rheumatoid 1

Interventions

Adalimumab 13 Methotrexate 11 Etanercept 10 Rituximab 5 Abatacept 5 tocilizumab 4 olokizumab 4 tofacitinib 3 golimumab 3 Infliximab 3 Tumor Necrosis Factor Inhibitors 2 Saline Solution 2 RC-18 2 Nivolumab 2 Leflunomide 2 Certolizumab Pegol 2 Antirheumatic Agents 2 veltuzumab 1 upadacitinib 1 secukinumab 1 sarilumab 1 mavrilimumab 1 entecavir 1 cabozantinib 1 baricitinib 1 andecaliximab 1 Vitamin D 1 Vaccines 1 TACI receptor-IgG Fc fragment fusion protein 1 Syringes 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Arthritis, Rheumatoid × Sulfasalazine × Clear all

NCT03449758 2022-04-28

SariPRO

Sanofi

Phase 4 Completed

84 enrolled 36 charts

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon ⚡